Tekla Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $27.2M | Hold |
143,214
| – | – | 1.06% | 25 |
|
|
2023
Q1 | $28.7M | Hold |
143,214
| – | – | 1.09% | 26 |
|
|
2022
Q4 | $34M | Hold |
143,214
| – | – | 1.29% | 23 |
|
|
2022
Q3 | $28.7M | Buy |
143,214
+14,800
| +12% | +$2.82M | 1.17% | 25 |
|
|
2022
Q2 | $18.7M | Sell |
128,414
-30,192
| -19% | -$4.28M | 0.74% | 33 |
|
|
2022
Q1 | $25.9M | Sell |
158,606
-31,089
| -16% | -$4.74M | 0.91% | 31 |
|
|
2021
Q4 | $32.2M | Hold |
189,695
| – | – | 1.04% | 29 |
|
|
2021
Q3 | $35.8M | Buy |
189,695
+55,200
| +41% | +$10.4M | 1.15% | 27 |
|
|
2021
Q2 | $22.8M | Sell |
134,495
-20,407
| -13% | -$2.99M | 0.74% | 36 |
|
|
2021
Q1 | $21.9M | Sell |
154,902
-19,992
| -11% | -$3.01M | 0.75% | 36 |
|
|
2020
Q4 | $22.7M | Hold |
174,894
| – | – | 0.8% | 37 |
|
|
2020
Q3 | $25.5M | Buy |
174,894
+49,027
| +39% | +$6.97M | 0.95% | 28 |
|
|
2020
Q2 | $18.6M | Sell |
125,867
-11,750
| -9% | -$1.58M | 0.71% | 32 |
|
|
2020
Q1 | $15M | Sell |
137,617
-6,178
| -4% | -$713K | 0.68% | 33 |
|
|
2019
Q4 | $16.6M | Sell |
143,795
-22,480
| -14% | -$2.24M | 0.63% | 37 |
|
|
2019
Q3 | $13.4M | Buy |
166,275
+4,903
| +3% | +$388K | 0.58% | 43 |
|
|
2019
Q2 | $11.7M | Buy |
161,372
+27,914
| +21% | +$2.14M | 0.48% | 52 |
|
|
2019
Q1 | $12.5M | Buy |
133,458
+7,282
| +6% | +$609K | 0.51% | 48 |
|
|
2018
Q4 | $9.2M | Hold |
126,176
| – | – | 0.39% | 53 |
|
|
2018
Q3 | $11M | Sell |
126,176
-4,200
| -3% | -$422K | 0.4% | 59 |
|
|
2018
Q2 | $12.8M | Hold |
130,376
| – | – | 0.49% | 47 |
|
|
2018
Q1 | $15.5M | Buy |
130,376
+15,410
| +13% | +$1.99M | 0.6% | 38 |
|
|
2017
Q4 | $14.6M | Hold |
114,966
| – | – | 0.56% | 39 |
|
|
2017
Q3 | $13.5M | Hold |
114,966
| – | – | 0.48% | 41 |
|
|
2017
Q2 | $9.17M | Sell |
114,966
-129,029
| -53% | -$8.25M | 0.34% | 61 |
|
|
2017
Q1 | $12.5M | Hold |
243,995
| – | – | 0.48% | 44 |
|
|
2016
Q4 | $9.13M | Hold |
243,995
| – | – | 0.39% | 60 |
|
|
2016
Q3 | $16.5M | Hold |
243,995
| – | – | 0.64% | 38 |
|
|
2016
Q2 | $13.5M | Buy |
243,995
+106,500
| +77% | +$6.71M | 0.55% | 45 |
|
|
2016
Q1 | $8.63M | Hold |
137,495
| – | – | 0.37% | 62 |
|
|
2015
Q4 | $12.9M | Sell |
137,495
-143,979
| -51% | -$13.3M | 0.47% | 45 |
|
|
2015
Q3 | $22.6M | Buy |
281,474
+177,979
| +172% | +$19.8M | 0.81% | 27 |
|
|
2015
Q2 | $12.4M | Sell |
103,495
-26,700
| -21% | -$3.19M | 0.45% | 46 |
|
|
2015
Q1 | $13.6M | Buy |
130,195
+68,600
| +111% | +$6.95M | 0.54% | 45 |
|
|
2014
Q4 | $5.97M | Hold |
61,595
| – | – | 0.28% | 68 |
|
|
2014
Q3 | $4.81M | Hold |
61,595
| – | – | 0.23% | 80 |
|
|
2014
Q2 | $3.89M | Hold |
61,595
| – | – | 0.36% | 50 |
|
|
2014
Q1 | $4.13M | Buy |
61,595
+12,900
| +26% | +$999K | 0.41% | 46 |
|
|
2013
Q4 | $3.13M | Buy |
48,695
+24,950
| +105% | +$1.49M | 0.33% | 47 |
|
|
2013
Q3 | $1.52M | Buy |
+23,745
| New | +$1.18M | 0.17% | 57 |
|
Other funds holding ALNY
Tekla Capital Management's ALNY Position: Q2 2023 in Review
Tekla Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2023 at 143,214 shares worth $27.2M. The position accounts for 1.06% of the portfolio, ranked #25.
Tekla Capital Management first reported a position in ALNY in Q3 2013 and has held it in 40 quarters since. The position peaked at $35.8M in Q3 2021. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.
- Tekla Capital Management held 143,214 shares of Alnylam Pharmaceuticals worth $27.2M as of Q2 2023.
- Tekla Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2023.
- Alnylam Pharmaceuticals made up 1.06% of Tekla Capital Management's portfolio in Q2 2023, its #25 holding.
- Tekla Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
- Tekla Capital Management's Alnylam Pharmaceuticals position peaked at $35.8M in Q3 2021.
- 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.